EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies.
暂无分享,去创建一个
Nancy L Oleinick | N. Oleinick | A. Gupta | Anirban Sen Gupta | Yizhi Qi | A. Master | Alyssa M Master | Yizhi Qi
[1] J. V. van Lier,et al. Targeted photodynamic therapy via receptor mediated delivery systems. , 2004, Advanced drug delivery reviews.
[2] T. Reimer,et al. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. , 2010, Deutsches Arzteblatt international.
[3] C. Allen,et al. Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. , 2006, Bioconjugate chemistry.
[4] H. Klok,et al. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. , 2001, Advanced drug delivery reviews.
[5] E. Zuhowski,et al. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent , 1999, Cancer Chemotherapy and Pharmacology.
[6] Baowei Fei,et al. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. , 2008, Journal of the American Chemical Society.
[7] D. Maysinger,et al. Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles. , 1999, Biochimica et biophysica acta.
[8] Kevin D Cooper,et al. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. , 2007, Toxicology and applied pharmacology.
[9] S. Barni,et al. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel , 2010, Expert opinion on pharmacotherapy.
[10] J. Vermorken,et al. Targeted therapies in head and neck cancer: past, present and future. , 2008, Reviews on recent clinical trials.
[11] R. Donehower,et al. Drug therapy : paclitaxel (Taxol) , 1995 .
[12] Marilena Loizidou,et al. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.
[13] Brian W Pogue,et al. Tumor PO(2) changes during photodynamic therapy depend upon photosensitizer type and time after injection. , 2002, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[14] T J Dougherty,et al. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. , 1975, Journal of the National Cancer Institute.
[15] Melinda Fitzgerald,et al. Immunol. Cell Biol. , 1995 .
[16] J Verweij,et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.
[17] P. Baldrick. Pharmaceutical excipient development: the need for preclinical guidance. , 2000, Regulatory toxicology and pharmacology : RTP.
[18] Indrajit Roy,et al. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. , 2007, Nano letters.
[19] Peter K. Kik,et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD) , 1999, British Journal of Cancer.
[20] H. Uludaǧ,et al. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. , 2007, Biomacromolecules.
[21] T. Foster,et al. Irradiation‐Induced Enhancement of Pc 4 Fluorescence and Changes in Light Scattering are Potential Dosimeters for Pc 4‐PDT † , 2007, Photochemistry and photobiology.
[22] T. Allen,et al. Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[23] Ming Yao,et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] C. Sibata,et al. Photosensitizers in clinical PDT. , 2004, Photodiagnosis and photodynamic therapy.
[25] L. Dubertret,et al. INTERACTION OF HUMAN SERUM LOW DENSITY LIPOPROTEINS WITH PORPHYRINS: A SPECTROSCOPIC AND PHOTOCHEMICAL STUDY , 1984, Photochemistry and photobiology.
[26] Christine Allen,et al. Nano-engineering block copolymer aggregates for drug delivery , 1999 .
[27] Jean-François Gohy,et al. Block copolymer micelles , 2005 .
[28] Zonghai Li,et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. , 2008, International journal of pharmaceutics.
[29] A. S. Sobolev,et al. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency , 2000, Immunology and cell biology.
[30] Zhuang Liu,et al. Folate-conjugated crosslinked biodegradable micelles for receptor-mediated delivery of paclitaxel , 2011 .
[31] J. Verweij,et al. Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.
[32] Vladimir P Torchilin,et al. Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.
[33] D. Maysinger,et al. Block copolymer micelles as delivery vehicles of hydrophobic drugs: Micelle–cell interactions , 2006, Journal of drug targeting.
[34] Cornelus F. van Nostrum,et al. Polymeric micelles to deliver photosensitizers for photodynamic therapy. , 2004 .
[35] N. Nishiyama,et al. Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. , 2009, Advanced drug delivery reviews.
[36] Kashif Azizuddin,et al. The Peripheral Benzodiazepine Receptor in Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4¶ , 2002, Photochemistry and photobiology.
[37] Lawrence X. Yu,et al. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. , 2011, Bioanalysis.
[38] H. Fearnhead. Getting Back on Track, or what to do when apoptosis is de-railed: Recoupling Oncogenes to the Apoptotic Machinery , 2004, Cancer biology & therapy.
[39] R. Singal,et al. EGFR targeting of solid tumors. , 2007, Cancer control : journal of the Moffitt Cancer Center.
[40] P. Morlière,et al. Photodynamic therapies: principles and present medical applications. , 2006, Bio-medical materials and engineering.
[41] Allan S. Hoffman,et al. The origins and evolution of "controlled" drug delivery systems. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[42] Xia Han,et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity , 2004, Molecular Cancer.
[43] Nancy L Oleinick,et al. The role of apoptosis in response to photodynamic therapy: what, where, why, and how , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[44] G. Tortora,et al. Rational bases for the development of EGFR inhibitors for cancer treatment. , 2007, The international journal of biochemistry & cell biology.
[45] Kshirsagar. Drug delivery systems , 2000 .
[46] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[47] I. Tan,et al. Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx , 2007, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.
[48] Myriam E. Rodriguez,et al. Delivery of the photosensitizer Pc 4 in PEG-PCL micelles for in vitro PDT studies. , 2010, Journal of pharmaceutical sciences.
[49] T. Hasan,et al. Targeted photodynamic therapy , 2006, Lasers in surgery and medicine.
[50] Alexander Gaitanis,et al. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. , 2010, Methods in molecular biology.
[51] Roy S Herbst,et al. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.
[52] Vladimir P. Torchilin,et al. Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles , 2007, Cancer biology & therapy.